Business Wire

PANASONIC

Share
Berlin’s First Smart City Quarter Powered by Panasonic

Panasonic is proud to announce the start of its innovative, CO2 -saving energy solution for the smart city project, Future Living® Berlin. The urban beacon is an important project in the company’s wider smart cities portfolio, which contribute to its focus on the decarbonization of society.

The installation in Berlin combines both green & sustainable and digital & connected living. It is realised through the installation of smart energy solutions including Panasonic’s highly efficient air to water heat pumps, photovoltaic (PV) panels and storage batteries integrated into an intelligent and efficient energy management system.

Junichi Suzuki, Chairman and CEO of Panasonic Europe B.V comments,

‘We bring to the project over 60 years of heating and cooling expertise alongside decades in PV and battery solutions, and a passion for innovations that will shape the future for generations to come. ‘

Panasonic has achieved strong sales growth in the relevant Energy business areas in Europe, e.g. double-digit sales growth in the air to water heat pump business for the last 10 years. The company has also committed in 2019 to grow the “Residential Energy Saving Equipment” business multiple times over by 2025.

Efficient Energy Management

For Panasonic, Future Living® Berlin is a fundamentally important experiment in building cutting-edge energy solutions. The project marks a milestone in achieving the goals set in the strategy.

Panasonic’s energy experts and software engineers of its R&D Centre in Europe have developed an intelligent energy management solution to optimize the use of energy and couple electricity with the heating sector. The smart control combines heat pumps together with other efficient, green Panasonic technologies, such as PV panels. The technologies have been integrated into an efficient energy saving solution not only controlled, but also constantly optimised by Panasonic’s intelligent energy management solution.

Ralf Becker, Project Leader Energy Group, Panasonic R&D Centre Europe explains,

‘The solution is a world first, developed with leading research institutions for decentralized energy management. In simulations together with university test labs we achieved an improvement of used energy by up to 15%.‘

A Beacon for Sustainable Living

The core energy component of the Future Living Berlin green & sustainable goal is the installed Panasonic’s air to water heat pump product line-up, ‘Aquarea’. A highly energy efficient technology, they run almost carbon-free when powered by the renewable energy provided by the 600 Panasonic HIT panels, which supply a capacity of 195kWp. On account of the patented silicone technology, the Panasonic photovoltaic system is 10% more efficient than conventional modules. Furthermore Panasonic’s HIT technology achieves a significantly better performance in hot environments because of its superior temperature coefficient – an essential advantage in coping with the climate change.

Utilising the renewable energy, the air to water system is used for space heating and warm water generation. For increased performance, the heat pumps include a cloud-based connectivity feature for installers called Aquarea Service Cloud which makes them even more reliable. It saves further CO2 emissions as maintenance visits can be organized much more efficiently and partly even conducted remotely.

These energy solutions are brought together under a Aquarea Smart Cloud, which allows end-users to monitor their power usage and manage temperature settings accordingly. This results in increased efficiency and comfort while enjoying transparency of their consumption.

To achieve further sustainable and green objectives, residents are part of a wider ecological environment which offers green car sharing, shared washing machines, and Panasonic energy solutions

Connected comfortability

The digital & connected goal of Future Living Berlin starts within the residential apartments. The equipment follows the idea of being smart and connected with Panasonic TVs and smart speakers being part of an overall IoT infrastructure, which includes an apartment manager as the central hub.

Digital & connected solutions are further extended to include wider security, safety, and smart building solutions that enhance the overall comfortability of residents.

Suzuki continues,

‘Future Living® Berlin is a future Way of Living – of how we may live tomorrow with a focus on social, digital & connected, and green & sustainable living.’

Panasonic is partnering in the smart city project with GSW Sigmaringen, the building-owner of Future Living® Berlin.

About Panasonic

Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 528 subsidiaries and 72 associated companies worldwide and reported consolidated net sales of 61.9 billion Euro (7.49 trillion yen) for the year ended March 31, 2020. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. To learn more about Panasonic: https://www.panasonic.com/global

IMAGES TO DOWNLOAD: https://www.flickr.com/photos/panasonic-europe/collections/72157714840244853/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye